CRISPR Therapeutics AG
CRSP
$56.25
-$0.43-0.76%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 38.34M | 38.05M | 37.68M | 37.31M | 202.83M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 38.34M | 38.05M | 37.68M | 37.31M | 202.83M |
| Cost of Revenue | 391.89M | 350.30M | 367.55M | 360.69M | 393.68M |
| Gross Profit | -353.55M | -312.25M | -329.87M | -323.38M | -190.85M |
| SG&A Expenses | 73.27M | 73.76M | 74.32M | 72.98M | 71.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 516.48M | 494.26M | 512.08M | 503.88M | 535.22M |
| Operating Income | -478.14M | -456.21M | -474.40M | -466.57M | -332.39M |
| Income Before Tax | -484.58M | -463.82M | -381.69M | -362.67M | -236.47M |
| Income Tax Expenses | 3.72M | 3.98M | 3.97M | 3.59M | 3.12M |
| Earnings from Continuing Operations | -488.30 | -467.80 | -385.66 | -366.25 | -239.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -488.30M | -467.80M | -385.66M | -366.25M | -239.59M |
| EBIT | -478.14M | -456.21M | -474.40M | -466.57M | -332.39M |
| EBITDA | -459.48M | -437.25M | -455.24M | -447.31M | -313.08M |
| EPS Basic | -5.58 | -5.42 | -4.52 | -4.36 | -2.80 |
| Normalized Basic EPS | -2.77 | -2.67 | -2.79 | -2.70 | -1.73 |
| EPS Diluted | -5.59 | -5.43 | -4.52 | -4.37 | -2.84 |
| Normalized Diluted EPS | -2.77 | -2.67 | -2.79 | -2.70 | -1.74 |
| Average Basic Shares Outstanding | 349.78M | 343.71M | 341.56M | 337.41M | 331.64M |
| Average Diluted Shares Outstanding | 349.78M | 343.71M | 341.56M | 337.41M | 333.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |